Dr. Judge is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
171 Ashley Ave
Charleston, SC 29425Phone+1 843-792-1414
Summary
- I am a board-certified specialist in Advanced Heart Failure & Transplant Cardiology, also boarded in Cardiovascular Disease. I direct the Cardiovascular Genetics program at Medical University of South Carolina, and I am also the Fellowship Program Director for Cardiovascular Disease at MUSC in Charleston, SC.
Education & Training
- Johns Hopkins UniversityFellowship, Cardiovascular Disease, 1996 - 2000
- Johns Hopkins UniversityResidency, Internal Medicine, 1993 - 1996
- Perelman School of Medicine at the University of PennsylvaniaClass of 1992
Certifications & Licensure
- SC State Medical License 2018 - 2025
- MD State Medical License 1996 - 2018
- American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
- American Board of Internal Medicine Cardiovascular Disease
Clinical Trials
- DCM Precision Medicine Study Start of enrollment: 2016 Jun 07
Publications & Presentations
PubMed
- Arrhythmogenic Cardiomyopathy: Towards Genotype Based Diagnoses and Management.Steven A Muller, Giorgia Bertoli, Jianan Wang, Alessio Gasperetti, Moniek G P J Cox
Journal of Cardiovascular Electrophysiology. 2024-12-02 - Characterization and natural history of patients with LMNA-related dilated cardiomyopathy in the phase 3 REALM-DCM trial.Pablo Garcia-Pavia, Neal K Lakdawala, Gianfranco Sinagra, Tomas Ripoll-Vera, Kia Afshar
ESC Heart Failure. 2024-12-01 - Underestimated risk of secondary complications in pathogenic and glucose-elevating GCK variant carriers with type 2 diabetes.Kelly M Schiabor Barrett, Natalie Telis, Lisa M McEwen, Evanette K Burrows, Basil Khuder
Communications Medicine. 2024-11-20
Press Mentions
- FDA Approves Acoramidis, BridgeBio’s New ATTR-CM DrugNovember 23rd, 2024
- New ATTR-CM Drug Linked to Positive Long-Term Data as FDA Nears Final DecisionNovember 22nd, 2024
- With Post Hoc Analysis, BridgeBio Touts Case for Acoramidis as FDA Decision Date Draws NearSeptember 30th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: